A. Van Mourik
Netherlands Cancer Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Van Mourik.
Radiotherapy and Oncology | 2016
J. Geuze; J. Kaas; T.A. Van de Water; A. Van Mourik; F. Wittkämper
S731 ________________________________________________________________________________ coverage and the conformity due to the dental implant for nasopharyngeal cancer(NPC) group (implant outside the PTV ).However, for the Non-NPC group (implant inside the PTV), a large discrepancy was obtained in all PTV parameters. There were statistically sig. differences(P<0.05) in PTVmax, PTVmean, Conformation Number and volume covered with 70Gy(V70Gy) among models.A large portion of PTV was underdosed.For the stainless steel, the V70Gy is below 70%, which is 25% poorer when compared with AAA plans. In the phantom study, ionization chamber and film measurements supported the dose perturbations by AXB. Using a 3% and 3mm criteria Gamma analysis, passing rate was between 95.0% and 99.7% demonstrating that AXB was in agreement with measurements in different models.
Radiotherapy and Oncology | 2016
E. Lamers-Kuijper; E. Van der Bijl; A. Van Mourik; C. Van Vliet-Vroegindeweij; E. Damen
ESTRO 35 2016 _____________________________________________________________________________________________________ Results: The mean GTV volumes ranged from 149.44 to 526.53 cc. VMAT plans show good results in comparison with 3DCRT in both conformity index (0.81±0.09 Vs 0.68±0.07 respectively, p-value of 0.009), and heterogeneity index (0.11±0.03 Vs 0.14±0.02, p value= 0.042). Furthermore, minimum doses to PTV in VMAT plans are higher than 3DCRT plans (57±1.22 Vs 55.1±0.86, p value= 0.001). In risk structures, the lung volume receiving 10Gy, 20Gy and 30Gy were reduced in VMAT plans (with relative reduction of 2.27%, p=0.002; 4.87%, p=0.001; 11.8% respectively). Mean lung dose was also reduced ( 15 Vs 17.69 ) but not statistically significant. V30 of the heart was reduced compared to 3DCRT (7.53±6.2 10.43±6.8 with p value of 0.051). The maximum dose of esophagus with VMAT was 47.7 Vs 48.69 with 3D CRT ( not statistically significant). Moreover, D 50 of the esophagus was less with VMAT ( 19.94 Vs 23.63) with p value of 0.22. Regarding monitor units, the mean values were ( 461.40±124.42 Vs 227.90±13.52) for VMAT and 3D CRT respectively.
Radiotherapy and Oncology | 2017
L. Wiersema; Gerben R. Borst; S. Nakhaee; H. Peulen; T. Wiersma; M. Kwint; A. Smit; M. Romp; P. Remeijer; A. Van Mourik
International Journal of Radiation Oncology Biology Physics | 2009
T.J. Yang; Paula H.M. Elkhuizen; D. Minkema; Wilma D. Heemsbergen; A. Van Mourik; Jorien Cassee; Coen W. Hurkmans; C van Vliet-Vroegindeweij
Radiotherapy and Oncology | 2018
E. Hessen; P. Damen; B. Jasperse; Luc Dewit; Paula H.M. Elkhuizen; A. Van Mourik; F. Wittkämper; E. Damen; U. Van der Heide; P. Hanssens; J. Schasfoort; Jasper Nijkamp; Gerben R. Borst
Radiotherapy and Oncology | 2018
C. Panneman; J. Kaas; A.M. Olszewska; T.A. Van de Water; A. Van Mourik; F. Wittkämper
Radiotherapy and Oncology | 2018
J. Stam; A. Licup; P. Remeijer; A. Van Mourik
Radiotherapy and Oncology | 2018
L. Wiersema; A. Licup; M. Buijs; A. Van Mourik; Gerben R. Borst; P. Remeijer
Photodiagnosis and Photodynamic Therapy | 2017
M.B. Karakullukçu; T.E.M. van Doeveren; R.L.P. van Veen; F. van der Boom; M. Smolic; A. Van Mourik; I.B. Tan
Radiotherapy and Oncology | 2016
K. De Vries; M. Beerendonk; Luc Dewit; W. Boogerd; D. Brandsma; A. Van Mourik; Gerben R. Borst